Q1 2026 earnings call recap: 57% sales growth, higher 2026 guidance, pharmacy mix gains, and FDA risk updates—read now.

IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial ...

Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +8.24% and -0.45%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

The consensus estimate for Q1 2026 revenue is $26.97 million, and the earnings are expected to come in at -$0.50 per share. The full year 2026's revenue is expected to be $132.59 million, and the ...

Beta Bionics, Inc. BBNX shares rallied 10.3% in the last trading session to close at $13.02. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Damiano, a professor at Boston University and the chief executive of a promising start-up called Beta Bionics, was there to support a new generation of continuous glucose monitoring technology – part ...

Advanced report intelligence delivers actionable guidance to improve outcomes for people using the iLet Bionic PancreasIRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Beta Bionics today announced ...

Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2026 financial results ...

Patch pump under development with commercialization expected by the end of 2027 One of Orange County’s fastest-growing public companies only went public two months ago. Beta Bionics Inc.’s concept of ...

Beta Bionics Inc., which makes ­a “bionic pancreas,” has secured $60 million in a Series E funding round led by new investor Wellington Management. The funding fuels Beta Bionics’ continued ...

Shares of Beta Bionics fell after the maker of insulin-delivery systems shared preliminary data for new patient starts that were below expectations. The stock slipped 36%, to $20.5, on Friday. Over ...